Category: Sanofi-Aventis
French healthcare giant Sanofi is the last buyer still in the running to acquire German Bayer's blood glucose management devices, a deal that may be worth more than $1.5 billion, sources say.
Johnson & Johnson, already the world's largest health products maker, could have its eye on Edwards Lifesciences and St. Jude Medical as potential acquisitions, analysts say.
Shire plc doubles down on its $750 million buyout of Advanced Biohealing with Pervasive Therapeutics and its endothelial cell technology; also, orthopedic bellwether Biomet's Q3 results signal sector growth; McKesson beats out rivals for $32B VA deal; Insulet expands OUS distribution deal; Revolutions Medical inks Korean distribution deal; Pluromed pays back $500k Mass. loan; plus, a Funding Roundup and analysts' ups and downs.
Shire (NSDQ:SHPGY) said it agreed to acquire Pervasis Therapeutics and its endothelial cell technology for an undisclosed amount.
Boston Scientific launches its BackStop kidney stone treatment, licensed from Pluromed, in the U.S. and certain international markets; also, Siemens lands 3rd year defense contract worth up to $1.9 billion; Bruker Corp. nabs all shares of SkyScan for an undisclosed amount; Viking expects 40% sales growth for Q1 2012; Smith & Nephew acquires LifeModeler for an undisclosed amount; Wound Care Innovations signs exclusive N.A.
Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.
French health giant Sanofi adds to its biosurgery portfolio with the acquisition of surgical hydrogel products maker Pluromed.
French health care giant Sanofi (NYSE:SNY) signed a definitive agreement to acquire hydrogel maker Pluromed for an undisclosed amount.
Sanofi plans to commercialize Woburn, Mass.-based Pluromed's LeGoo polymer plug, an injectable gel used during surgical procedures in place of a clamp or snare.
The Wall Street Journal's tech columnist, Walt Mossberg, calls Telcare's cellular-enabled glucose monitor "a leap ahead of nearly all glucose meters."
Telcare Inc. got high marks for its cellular-enabled glucose monitor from the Wall Street Journal's personal technology columnist, Walt Mossberg.
While he didn't love the outdated look of the device, which he describes as looking like a "thick, old cellphone," he called the Telcare system "a leap ahead of nearly all glucose meters."
The Telcare BGM is a 3G wireless-enabled glucose meter that can sent instantly send readings to a password-protected website, which can then be shared with doctors or family members, or to an iPhone app.
The top seven medical device stories for the week of December 5, 2011.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.
